nivolumab,ipilimumab
bms
['improve ', 'kcsm,(-skcsm)', 'rcc,(-irccs),(-srcc),(-urcc)', 'nivo', 'nivolumab', 'ipilimumab']
adjuvant nivolumab plus ipilimumab fails to improve dfs in localized, high-risk rcc #kcsm #esmo2022 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.